Literature DB >> 18725821

Perceptions of Iowa family physicians regarding colorectal cancer screening.

Barcey T Levy1, Mrinalini Joshi, Yinghui Xu, Jeanette Daly, Paul A James.   

Abstract

BACKGROUND: Fewer than half of Americans have been screened for colorectal cancer (CRC), a largely preventable disease.
METHODS: All physician members (n = 1030) of the Iowa Academy of Family Physicians were mailed a 3-page investigator-developed survey about their attitudes, barriers, and practices regarding CRC screening.
RESULTS: The usable response rate was 29%. Forty-three percent practiced in rural settings. Ninety-five percent felt that they were well informed about American Cancer Society guidelines and 90% tried to follow the guidelines. Most doctors (88%) disagreed with the statement that there was "no time to adequately discuss screening," but they would like more time to discuss screening. Only 40% felt their medical records were organized to easily determine screening status, 40% encouraged office staff to participate in screening, and 16% had a written policy regarding CRC screening. Physicians estimated that they recommend screening to 78% of their patients and that 54% of their patients were actually up-to-date. Discussion of CRC screening was strongly dependent on visit type, with physicians estimating that CRC screening is discussed at 11% of acute visits, 42% of chronic visits, and 87% of health maintenance visits. Several office system factors were associated with a recommendation for screening in a multivariable linear regression model (R = 0.33).
CONCLUSIONS: Although nearly all physicians felt that they were well informed about American Cancer Society guidelines and tried to follow guidelines for CRC screening, few had office systems to facilitate screening. Physicians would like more time to discuss screening. Office systems likely have the most potential to improve CRC screening among patients attending primary care practices.

Entities:  

Mesh:

Year:  2008        PMID: 18725821     DOI: 10.1097/MLR.0b013e31817c6100

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  7 in total

1.  Primary care, economic barriers to health care, and use of colorectal cancer screening tests among Medicare enrollees over time.

Authors:  Chyke A Doubeni; Adeyinka O Laiyemo; Angela C Young; Carrie N Klabunde; George Reed; Terry S Field; Robert H Fletcher
Journal:  Ann Fam Med       Date:  2010 Jul-Aug       Impact factor: 5.166

2.  Risk assessment and clinical decision making for colorectal cancer screening.

Authors:  Paul C Schroy; Sarah E Caron; Bonnie J Sherman; Timothy C Heeren; Tracy A Battaglia
Journal:  Health Expect       Date:  2013-07-30       Impact factor: 3.377

3.  Mailed fecal-immunochemical test for colon cancer screening.

Authors:  Jeanette M Daly; Barcey T Levy; Mary L Merchant; Jason Wilbur
Journal:  J Community Health       Date:  2010-06

4.  Using theory to predict implementation of a physician-pharmacist collaborative intervention within a practice-based research network.

Authors:  David E Demik; Mark W Vander Weg; Emily S Lundt; Christopher S Coffey; Gail Ardery; Barry L Carter
Journal:  Res Social Adm Pharm       Date:  2013-03-16

5.  System Strategies for Colorectal Cancer Screening at Federally Qualified Health Centers.

Authors:  Jeanette M Daly; Barcey T Levy; Carol A Moss; Camden P Bay
Journal:  Am J Public Health       Date:  2015-01       Impact factor: 9.308

6.  Physician visits and colorectal cancer testing among Medicare enrollees in North Carolina and South Carolina, 2005.

Authors:  Anna P Schenck; Carrie N Klabunde; Joan L Warren; Eric Jackson; Sharon Peacock; Pauline Lapin
Journal:  Prev Chronic Dis       Date:  2011-08-15       Impact factor: 2.830

7.  Comparative effectiveness of five fecal immunochemical tests using colonoscopy as the gold standard: study protocol.

Authors:  Barcey T Levy; Jeanette M Daly; Yinghui Xu; Seth D Crockett; Richard M Hoffman; Jeffrey D Dawson; Kim Parang; Navkiran K Shokar; Daniel S Reuland; Marc J Zuckerman; Avraham Levin
Journal:  Contemp Clin Trials       Date:  2021-05-08       Impact factor: 2.261

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.